• Explore /
  • Poster
  • / TALAPRO-3: A phase 3, double-blind, randomized study of enzalutamide (ENZA) plus talazoparib (TALA) vs placebo plus ENZA in patients with DDR gene-mutated, metastatic castration-sensitive prostate cancer (mCSPC).

TALAPRO-3: A phase 3, double-blind, randomized study of enzalutamide (ENZA) plus talazoparib (TALA) vs placebo plus ENZA in patients with DDR gene-mutated, metastatic castration-sensitive prostate cancer (mCSPC).

Abstract Video & Slides Poster

Authors

Neeraj Agarwal

Neeraj Agarwal

Huntsman Cancer Institute at the University of Utah, Salt Lake City, UT

Neeraj Agarwal , Fred Saad , Arun Azad , Joaquin Mateo , Nobuaki Matsubara , Neal D. Shore , Jayeta Chakrabarti , Hsiang-Chun Chen , Silvana Lanzalone , Alexander Niyazov , Karim Fizazi

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2023 ASCO Genitourinary Cancers Symposium

Session Type

Trials in Progress Poster Session

Session Title

Trials in Progress Poster Session A: Prostate Cancer

Track

Prostate Cancer - Advanced,Prostate Cancer - Localized

Sub Track

Therapeutics

Clinical Trial Registration Number

NCT04821622

Citation

J Clin Oncol 41, 2023 (suppl 6; abstr TPS279)

DOI

10.1200/JCO.2023.41.6_suppl.TPS279

Abstract #

TPS279

Poster Bd #

Q1

Abstract Disclosures

Similar Posters

First Author: Neeraj Agarwal

First Author: Neeraj Agarwal

First Author: Johann S. De Bono

First Author: Pedro C. Barata